HOLON, Israel, August 7, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery
and development of first-in-class therapeutics for cancer
immunotherapy, announced today that CGEN-15032, a newly-disclosed
novel myeloid and epithelial immuno-oncology target, will be the
subject of both an oral and a poster presentation at the 3rd annual
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
taking place September 6-9, 2017 in
Mainz/Frankfurt, Germany.
The presentation titled "Computational discovery and
experimental validation of CGEN-15032 as a novel target for cancer
immunotherapy" is scheduled as part of the session titled "Other
checkpoint blocking and immunomodulating antibodies," on
Friday, September 8, 2:00-3:45 pm CEST.
The poster will be presented during the "Checkpoint Blockade
Therapy" poster session on Wednesday,
September 6, 6:00-8:00 pm CEST
(Abstract A146).
CGEN-15032 belongs to a portfolio of novel myeloid and lymphoid
target candidates discovered by the Company that are expressed
within the tumor microenvironment (TME) of multiple cancers. These
targets were discovered using various discovery platforms developed
by the Company, including the immune checkpoint discovery platform
and immuno-modulatory protein discovery platforms. A number of
these targets have demonstrated in vitro checkpoint activity, and a
knockout mouse strain for one of them demonstrated reduced tumor
growth inhibition in vivo relative to wild type mice. Furthermore,
the reduced tumor growth was observed in both the knockout mice
alone and when the mice were treated with an anti-PD-L1 inhibitor.
Drug candidates against these targets could have the potential to
treat both PD-1 responsive and non-responsive patients.
Additional information, not previously disclosed, about the
Company's new myeloid and lymphoid targets can be found in an
updated corporate presentation (slides 22-24; 44-48) posted on
Compugen's website at http://www.cgen.com.
Following the presentation, the poster will be available on
Compugen's website.
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," and "intends," and describe opinions about possible
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen's business model is substantially dependent on entering
into collaboration agreements with third parties and Compugen may
not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission (SEC) as well as other documents that may be
subsequently filed by Compugen from time to time with the SEC. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
SOURCE Compugen Ltd.